Sodium-glucose co-transporter 2: Difference between revisions

	WikiDoc Resources for Sodium-glucose co-transporter 2
Articles
Most recent articles on Sodium-glucose co-transporter 2 Most cited articles on Sodium-glucose co-transporter 2 Review articles on Sodium-glucose co-transporter 2 Articles on Sodium-glucose co-transporter 2 in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Sodium-glucose co-transporter 2 Images of Sodium-glucose co-transporter 2 Photos of Sodium-glucose co-transporter 2 Podcasts & MP3s on Sodium-glucose co-transporter 2 Videos on Sodium-glucose co-transporter 2
Evidence Based Medicine
Cochrane Collaboration on Sodium-glucose co-transporter 2 Bandolier on Sodium-glucose co-transporter 2 TRIP on Sodium-glucose co-transporter 2
Clinical Trials
Ongoing Trials on Sodium-glucose co-transporter 2 at Clinical Trials.gov Trial results on Sodium-glucose co-transporter 2 Clinical Trials on Sodium-glucose co-transporter 2 at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Sodium-glucose co-transporter 2 NICE Guidance on Sodium-glucose co-transporter 2 NHS PRODIGY Guidance FDA on Sodium-glucose co-transporter 2 CDC on Sodium-glucose co-transporter 2
Books
Books on Sodium-glucose co-transporter 2
News
Sodium-glucose co-transporter 2 in the news Be alerted to news on Sodium-glucose co-transporter 2 News trends on Sodium-glucose co-transporter 2
Commentary
Blogs on Sodium-glucose co-transporter 2
Definitions
Definitions of Sodium-glucose co-transporter 2
Patient Resources / Community
Patient resources on Sodium-glucose co-transporter 2 Discussion groups on Sodium-glucose co-transporter 2 Patient Handouts on Sodium-glucose co-transporter 2 Directions to Hospitals Treating Sodium-glucose co-transporter 2 Risk calculators and risk factors for Sodium-glucose co-transporter 2
Healthcare Provider Resources
Symptoms of Sodium-glucose co-transporter 2 Causes & Risk Factors for Sodium-glucose co-transporter 2 Diagnostic studies for Sodium-glucose co-transporter 2 Treatment of Sodium-glucose co-transporter 2
Continuing Medical Education (CME)
CME Programs on Sodium-glucose co-transporter 2
International
Sodium-glucose co-transporter 2 en Espanol Sodium-glucose co-transporter 2 en Francais
Business
Sodium-glucose co-transporter 2 in the Marketplace Patents on Sodium-glucose co-transporter 2
Experimental / Informatics
List of terms related to Sodium-glucose co-transporter 2

solute carrier family 5 (sodium/glucose cotransporter), member 2
Identifiers
Symbol	SLC5A2
Alt. symbols	SGLT2
Entrez	6524
HUGO	11037
OMIM	182381
RefSeq	NM_003041
UniProt	P31639
Other data
Locus	Chr. 16 p11.2

VisualWikitext

Latest revision as of 04:10, 29 September 2015

Overview

Sodium-dependent glucose cotrasporter 2 are a family of glucose transporter "expressed in the luminal membrane of the proximal kidney tubules"^[1]. They contribute to renal glucose reabsorption.

Pharmacology

Inhibitors

Canagliflozin
Dapagliflozin
Empagliflozin
Gliflozin

Inhibitors improve glycemic control^[2] and may reduce clinical outcomes^[3].

References

↑ Anonymous 2015, co-transporter 2 Sodium-glucose co-transporter 2. Medical Subject Headings. U.S. National Library of Medicine.
↑ Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E; et al. (2013). "Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis". Ann Intern Med. 159 (4): 262–74. doi:10.7326/0003-4819-159-4-201308200-00007. PMID 24026259. Review in: Ann Intern Med. 2014 Jan 21;160(2):JC10
↑ Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S; et al. (2015). "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes". N Engl J Med. doi:10.1056/NEJMoa1504720. PMID 26378978.

External links

Sodium-Glucose+Transporter+2 at the US National Library of Medicine Medical Subject Headings (MeSH)

[1] Anonymous 2015, co-transporter 2 Sodium-glucose co-transporter 2. Medical Subject Headings. U.S. National Library of Medicine.

[pmid24026259-2] Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E; et al. (2013). "Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis". Ann Intern Med. 159 (4): 262–74. doi:10.7326/0003-4819-159-4-201308200-00007. PMID 24026259. Review in: Ann Intern Med. 2014 Jan 21;160(2):JC10

[pmid26378978-3] Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S; et al. (2015). "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes". N Engl J Med. doi:10.1056/NEJMoa1504720. PMID 26378978.

[1]

[2]

[3]

@@ Line 1: / Line 1: @@
-'''Sodium-dependent glucose cotrasporter 2''' are a family of [[glucose transporter]] expressed in the luminal membrane of the [[proximal kidney tubule]]s. They contribute to [[renal glucose reabsorption]].{{MeSH|Sodium-Glucose Transporter 2}}
+{{protein
+| Name = solute carrier family 5 (sodium/glucose cotransporter), member 2
+| caption =
+| image =
+| width =
+| HGNCid = 11037
+| Symbol = SLC5A2
+| AltSymbols = SGLT2
+| EntrezGene = 6524
+| OMIM = 182381
+| RefSeq = NM_003041
+| UniProt = P31639
+| PDB =
+| ECnumber =
+| Chromosome = 16
+| Arm = p
+| Band = 11.2
+| LocusSupplementaryData =
+}}
+{{SI}}
+==Overview==
+'''Sodium-dependent glucose cotrasporter 2''' are a family of [[glucose transporter]] "expressed in the luminal membrane of the [[proximal kidney tubule]]s"<ref> Anonymous 2015, [http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?term={{PAGENAME}} {{PAGENAME}}]. Medical Subject Headings. U.S. National Library of Medicine.</ref>. They contribute to [[renal glucose reabsorption]].
+==Pharmacology==
+===Inhibitors===
+* Canagliflozin
+* Dapagliflozin
+* Empagliflozin
+* Gliflozin
+Inhibitors improve glycemic control<ref name="pmid24026259">{{cite journal| author=Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E et al.| title=Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. | journal=Ann Intern Med | year= 2013 | volume= 159 | issue= 4 | pages= 262-74 | pmid=24026259 | doi=10.7326/0003-4819-159-4-201308200-00007 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24026259  }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24445708 Review in: Ann Intern Med. 2014 Jan 21;160(2):JC10] </ref> and may reduce clinical outcomes<ref name="pmid26378978">{{cite journal| author=Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al.| title=Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. | journal=N Engl J Med | year= 2015 | volume=  | issue=  | pages=  | pmid=26378978 | doi=10.1056/NEJMoa1504720 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26378978  }} </ref>.
+==References==
+<references/>
+==External links==
+* {{MeshName|Sodium-Glucose+Transporter+2}}
+{{Ion pumps}}
+{{Membrane transport proteins}}